Cellectar Biosciences, Inc. — Director's Dealing 2022

Aug 2, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cellectar Biosciences, Inc. (CLRB)
CIK: 0001279704
Period of Report: 2022-06-24

Reporting Person: NEIS JOHN (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-24	Stock option (right to buy)	$4.10	A	7800	Acquired	2032-06-24	Common Stock (7800)	Direct

Footnotes

F1: Exercise price and quantity have been adjusted for the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022.

F2: This stock option shall vest in full on June 24, 2023, subject to the reporting person's continued service through the applicable vesting date.